

Supporting Information © Wiley-VCH 2012

69451 Weinheim, Germany

Total Synthesis of Neurymenolide A Based on a Gold-Catalyzed Synthesis of 4-Hydroxy-2-pyrones**


Wojciech Chaładaj, Matthieu Corbet, and Alois Fürstner*

anie_201203180_sm_miscellaneous_information.pdf

General. All reactions were carried out in flame-dried glassware under Argon. All solvents were purified by distillation over the drying agents indicated and were transferred under Argon: THF (Mg-anthracene), diethyl ether (Mg-anthracene), dichloromethane (CaH₂), acetonitrile (CaH₂), triethylamine (CaH₂), hexane (Na/K), toluene (Na/K). HOAc and MeOH were used as received. Flash chromatography: Merck silica gel 60 (230-400 mesh). IR: Nicolet FT-7199 spectrometer, wavenumbers in cm⁻¹. MS (EI): Finnigan MAT 8200, MS (CI): Finnigan MAT 95, MS (ESI) ESQ 3000; accurate mass determinations: Bruker APEX III FT-MS (7 T magnet). NMR: Spectra were recorded on a Bruker DPX 300, AV 400 or AV 500 spectrometer in the solvents indicated; ¹H and ¹³C chemical shifts (δ) are given in ppm relative to TMS, coupling constants (*J*) in Hz. The solvent signals were used as references (CDCl₃ δ_{H} = 7.24 ppm, δ_{C} = 77.0 ppm; C₆D₆ δ_{H} = 7.15 ppm, δ_{C} = 128.00 ppm; [D₆]-DMSO δ_{H} = 2.50 ppm, δ_{C} = 39.5 ppm; D₃COD δ_{H} = 3.31 ppm, δ_{C} = 49.00 ppm) and the chemical shifts converted to the TMS scale. Unless stated otherwise, all commercially available compounds (ABCR, Acros, Aldrich, Fluka, Lancaster, Strem) were used as received.

New Gold-Catalyzed Synthesis of 4-Hydroxy-2-pyrones. Pseudopyronine A


Compound 6g (R¹ = hexyl, R² = pentyl). *t*-Butyl octanoate (1.0 g, 0.5 mmol) was added dropwise to a



stirred solution of LDA (0.5 mmodemu in THF, 10 mL, 5 mmol) at -78 °C. The mixture was stirred at this temperature for 30 min before methyl 2-octynoate (771 mg, 0.5 mmol) was slowly introduced and stirring continued at -78 °C for 2 h. The mixture was poured into aq. sat. NH₄Cl (50 mL) and the organic phase

extracted with Et₂O (3 x 50 mL), dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica, hexanes/EtOAc, 99:1 \rightarrow 95:5) gave keto ester **6g** as a colorless oil (1.34 g, 83 %). ¹H NMR (400 MHz, CDCl₃, mixture of keto/enol tautomers): δ = 0.85-0.93 (m, 6H), 1.23-1.43 (m, 12H), 1.46 & 1.50 (s each, Σ 9H), 1.53-1.62 (m, 2H), 1.80-1.93 (m, 1H), 2.22-2.29 (m, 1H), 2.36 (t, *J* = 7.1, 1H), 2.40 (t, *J* = 7.1, 1H), 3.33 (t, *J* = 7.4, 0.5H), 12.33 (s, 0.5H); ¹³C NMR (100 MHz, CDCl₃): δ = 13.8, 13.9, 14.0, 14.0, 19.0, 19.4 22.0, 22.1, 22.5, 22.6, 27.0, 17.3, 27.8, 27.9, 28.1, 28.2, 28.9, 29.0, 29.6, 30.9, 31.0, 31.5, 31.6, 61.9, 75.0, 79.6, 81.6, 81.7, 96.3, 99.2, 109.4, 152.3, 168.2, 172.8, 183.3. IR (film): \tilde{V} = 2957, 2929, 2859, 2214, 1736, 1677, 1633, 1598, 1457, 1369, 1358, 1250, 1150, 1128, 845, 820; MS (EI): *m/z* (%) 322 (4), 266 (45), 249 (15), 238 (5), 223 (23), 210 (13), 195 (23), 177 (20), 139 (11), 123 (95), 98 (71), 82 (9), 67 (23), 57 (100), 41 (38); HRMS (EI): *m/z*: calcd for C₂₀H₃₄O₃Na [*M*+*Na*⁺]: 345.24001, found: 345.23988.

Representative Procedure for the Preparation of 4-Hydroxy-2-pyrones. Synthesis of



Pseudopyronine A (7g). A solution of substrate **6g** (325 mg, 1.0 mmol) and SPhosAuNTf₂ (**8**) (9 mg, 10 μ mol, 1 mol%) in HOAc (5 mL) was stirred for 24 h before the acid was distilled off and the residue purified by flash chromatography (silica, hexane/HOAc, 4:1) to afford pseudopyronine A (**7g**) as a white solid (257 mg, 96 %). Mp = 111.5-112.5 °C (lit. 106-108 °C).¹ ¹ H

NMR (400 MHz, CDCl₃): δ = 0.86-0.93 (m, 6H), 1.24-1.38 (m, 10H), 1.44-1.54 (m, 2H), 1.58-1.68 (m, 2H), 2.40-2.48 (m, 4H), 6.20 (s, 1H), 10.19 (br s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 13.9, 14.1, 22.3, 22.7, 23.1, 26.5, 28.0, 29.3, 31.1, 31.8, 33.5, 100.9, 103.4, 163.6, 167.2, 168.4; ¹H NMR (400 MHz, CDCl₃) = 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5, 16.5

¹ Giddens, A. C.; Nielsen, L.; Boshoff, H. I.; Tasdemir, D.; Perozzo, R.; Kaiser, M.; Wang, F.; Sacchettini, J. C.; Copp, B. R. *Tetrahedron* **2008**, *64*, 1242-1249.

CD₃OD): $\delta = 0.89$ (t, J = 7.0, 3H), 0.92 (t, J = 7.0, 3H), 1.32-1.40 (m, 10H), 1.40-1.50 (m, 2H), 1.60-1.70 (m, 2H), 2.37 (t, J = 7.5, 2H), 2.46 (t, J = 7.6, 2H), 4.89 (br s, 1H), 5.98 (s, 1H); ¹³C NMR (100 MHz, CD₃OD): $\delta = 14.2, 14.4, 23.4, 23.7, 23.9, 27.6, 29.0, 30.2, 32.2, 32.9, 34.2, 101.0, 103.9, 165.1, 167.7, 168.8; IR (film): <math>\tilde{V} = 2955, 2926, 2872, 2858, 2643, 1663, 1630, 1556, 1433, 1407, 1292, 1256, 1172, 1130, 992, 856, 758; MS (EI): <math>m/z$ (%) 266 (17), 249 (3), 237 (3), 223 (11), 209 (14), 195 (100), 182 (9), 168 (19), 153 (10), 140 (15), 126 (11), 111 (7), 99 (11), 83 (4), 69 (10), 55 (21), 43 (21); HRMS (ESI–): m/z: calcd for C₁₆H₂₅O₃ [M-H]⁻: 265.18092, found: 265.18085.




Figure S1. Analysis of the ¹H NMR data of compounds **7a** and **7c** (6-*endo* product) and comparison with known data for the tetronic acid (5-*exo* product) established their structures.

Compound 7a. Prepared analogously as colorless crystals (655 mg, 94%); after washing with Et₂O, the

material was found analytically pure, thus requiring no flash chromatography. Mp = 106–107 °C (lit:^{2a} 83 °C); ¹H NMR (400 MHz, CDCl₃): δ = 11.33 (br s, 1 H), 6.02 (dt, *J* = 2.0, 1.0 Hz, 1 H), 5.59 (d, *J* = 2.0 Hz, 1 H), 2.52 (q, *J* = 7.5 Hz, 2 H), 1.20 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 172.9 (C), 168.5 (C), 168.3 (C), 100.6 (CH), 89.7 (CH), 26.8 (CH₂), 10.8 (CH₃); IR (film): $\tilde{\nu}$ = 2984, 2950, 2566, 1650, 1614, 1574, 1543, 1446, 1383, 1366, 1311, 1283, 1266, 1242, 1203, 1139, 937, 883, 835, 808, 782, 693, 661 cm⁻¹; MS (EI): *m/z* (%): 140 (37) [*M*⁺], 111 (70), 99 (16), 69 (100), 57 (26), 29 (24); HRMS (EI): *m/z*: calcd for C₇H₈O₃ [*M*⁺]: 140.0473, found: 140.0472. The spectroscopic data are in good agreement with the data reported in the literature.²

Compound 7b. Prepared analogously as a white solid (14.9 mg, 97%); after washing with Et₂O, the material was found analytically pure, thus requiring no flash chromatography. ¹H NMR (400 MHz, [D₆]-DMSO): $\delta = 11.08$ (br s, 1 H), 5.96 (br s, 1 H), 2.43 (q, J = 7.5 Hz, 2 H), 1.74 (s, 3 H), 1.09 (t, J = 7.5 Hz, 3 H); ¹³C NMR (100 MHz, [D₆]-DMSO): $\delta = 165.0$ (C), 164.9 (C), 163.8 (C), 98.2 (CH), 96.5 (C), 25.9 (CH₂), 10.9 (CH₃), 8.3 (CH₃); IR (film): $\tilde{V} = 2984$, 2967, 2914, 2690, 1671, 1634, 1574, 1508, 1428, 1399, 1373, 1353, 1315, 1238, 1180, 1122, 1088, 1056, 1020, 947, 930, 845, 831, 752, 743, 667 cm⁻¹; MS (EI): m/z (%): 154 (88) [M^+], 126 (79), 111 (100), 99 (59), 83 (14), 69 (94); HRMS (EI): m/z: calcd for C₈H₁₀O₃ [M^+]: 154.0630, found: 154.0631.

 ² (a) Schmidt, D.; Conrad, J.; Klaiber, I.; Beifuss, U. *Chem. Commun.* 2006, 4732–4734. (b) Zhang, X.; McLaughlin, M.; Muñoz, R. L. P.; Hsung, R. P.; Wang, J.; Swidorski, J. *Synlett* 2007, 749–753.

Compound 7c. Prepared analogously as a white solid (18.7 mg, 99%); after washing with Et₂O, the material was found analytically pure, thus requiring no flash chromatography. ¹H NMR (400 MHz, [D₆]-DMSO): δ = 11.85 (br s, 1 H), 7.84 (m, 2 H), 7.51 (m, 3 H), 6.75 (d, *J* = 1.9 Hz, 1 H), 5.40 (d, *J* = 1.9 Hz, 1 H); ¹³C NMR (100 MHz, [D₆]-DMSO): δ = 170.5 (C), 163.0 (C), 160.1 (C), 131.1 (C), 130.9 (CH), 129.1 (2 × CH), 125.5 (2 × CH), 98.4 (CH), 89.6 (CH) ppm. The analytical data matched those reported in the literature.^{2a,3}


Compound 7d. Prepared analogously as a white solid (18.6 mg, 82%); after washing with Et₂O, the material was found analytically pure, thus requiring no flash chromatography. Mp = 187-195 °C (decomp.); ¹H NMR (400 MHz, [D₆]-DMSO): δ = 1.11 (t, *J* = 7.5, 3H), 2.48 (dq, *J* = 7.5, 0.8, 2H), 6.08 (t, *J* = 0.8, 1H), 12.53 (br s, 1H); ¹³C NMR (100 MHz, [D₆]-DMSO): δ = 10.7, 25.7, 84.9, 98.2, 160.4, 165.8, 166.7; IR (film): $\tilde{\nu}$ = 3082, 1656, 1565, 1428, 1411, 1380, 1326, 1222, 1157, 1048, 971, 943, 844, 791, 773, 741, 683; MS (EI): *m/z* (%) 220 (96), 218 (97), 192 (53), 190 (57), 177 (15), 175 (16), 163 (21), 161 (22), 135 (36), 133 (35), 122 (12), 120 (11), 111 (8), 99 (100), 83 (11), 69 (25), 57 (30), 53 (29), 39 (12), 29 (27); HRMS (EI): *m/z*: calcd for C₇H₆O₃Br [*M*+*Na*⁺]: 216.95059, found: 216.95071.

Compound 7e. Prepared analogously as a white solid (17.5 mg, 85%); after washing with Et₂O, the

material was found analytically pure, thus requiring no flash chromatography. ¹H NMR (400 MHz, $[D_6]$ -DMSO): $\delta = 12.38$ (br s, 1 H), 7.78 (m, 2 H), 7.51 (m, 3 H), 6.83 (d, J = 5.3Ph \sim Hz, 1 H); ¹³C NMR (100 MHz, $[D_6]$ -DMSO): $\delta = 157.1$ (d, $J_{CF} = 23.7$ Hz, C), 154.9 (d, $J_{CF} = 6.0$ Hz, C), 153.8 (d, $J_{CF} = 9.2$ Hz, C), 133.0 (C), 130.7 (CH), 130.4 (C), 129.1 (2 × CH), 125.3 (2 × CH), 98.9 (CH); IR (film): $\tilde{V} = 2885$, 2641, 2587, 2551, 1625, 1577, 1549, 1495, 1453, 1399, 1356, 1174, 1071, 1048, 910, 859, 824, 770, 734, 685, 658 cm⁻¹; MS (EI): m/z (%): 206 (100) [M^+], 178 (27), 149 (21), 130 (18), 105 (42), 77 (53), 51 (27); HRMS (ESI+): m/z: calcd for C₁₁H₇O₃FNa [M^+ + Na]: 229.0271, found: 229.0274.

Compound 7f. Prepared analogously as a white solid (8.3 mg, 45%). Mp = 116-118 °C; ¹H NMR (400

Compound 7h. Prepared analogously as a yellow solid (26.2 mg, 98%); after washing with Et₂O, the



material was found analytically pure. Because of the low solubility, flash chromatography results in loss of material. Mp = 239-242°C (decomp.); ¹H NMR (400 MHz, [D₆]-DMSO): δ = 5.30 (d, *J* = 2.0, 1H), 6.07 (s, 2H), 6.13 (d, *J* = 1.8, 1H), 6.88 (d, *J* = 16.0, 1H), 6.95 (d, *J* = 8.0, 1H), 7.14 (dd, *J* = 8.1, 1.4, 1H), 7.23 (d, *J* = 16.0, 1H), 7.33 (d, *J* = 1.4, 1H), 11.69 (br s, 1H); ¹³C NMR (100 MHz, [D₆]-

DMSO): δ = 89.6, 101.1, 101.4, 106.0, 108.5, 118.0, 123.6, 129.7, 133.9, 148.0, 148.4, 159.4, 162.9, 170.1; IR (film): \tilde{v} = 1699, 1631, 1606, 1555, 1499, 1479, 1443, 1357, 1299, 1254, 1241, 1157, 1100, 1036, 1009, 959, 924, 840, 815, 796, 683; MS (EI): m/z (%) 258 (100), 241 (7), 230 (6), 214 (21), 199 (11), 188 (45), 175 (30), 160 (25), 145 (25), 130 (16), 117 (16), 102 (12), 89 (35), 77 (6), 69 (26), 51 (10), 39 (11), 29 (5); HRMS (EI): m/z: calcd for C₁₄H₁₀O₅Na [M+ Na^+]: 281.04204, found: 281.04205.

³ Katritzky, A. R.; Wang, Z.; Wang, M.; Hall, C. D.; Suzuki, K. *J. Org. Chem.* **2005**, *70*, 4854–4856.

2-(Benzyloxy)-6-ethyl-2*H***-pyran-4-one (10).** Prepared analogously as a white solid (21.6 mg, 94%). Mp = 75-76 °C; ¹H NMR (400 MHz, CDCl₃): δ = 1.21, (t, *J* = 7.5, 3H), 2.51 (dt, *J* = 7.5, 0.5, 2H), 5.09 (s, 2H), 5.54 (d, *J* = 1.8, 1H), 5.99 (m, *J* = 1.8, 1H), 7.35-7.44 (m, 5H); ¹H NMR (400 MHz, CDCl₃): δ = 10.7, 26.2, 71.2, 90.9, 111.1, 127.9, 128.9, 129.0, 133.7, 166.4, 167.1, 181.9; IR (film): \tilde{V} = 3051, 2973, 2914, 1656, 1615, 1589, 1575, 1500,

1455, 1416, 1380, 1366, 1302, 1251, 1226, 103, 1157, 1091, 1059, 1029, 1005, 978, 924, 898, 800, 787, 740, 691, 681, 670; MS (EI): *m/z* (%) 230 (1) 174 (1), 132 (15), 91 (100), 77 (1), 65 (9), 51 (1), 40 (3), 29 (2) HRMS (EI): *m/z*: calcd for C₁₄H₁₄O₃Na [*M*+*Na*⁺]: 253.08351, found: 253.08334.

Total Synthesis of Neurymenolide A

(Z)-1-(Trimethylsilyl)oct-5-en-1-yn-3-ol (12). n-BuLi (1.6 M in hexane, 32 mL, 51 mmol) was added ΟН slowly to a stirred solution of ethynyltrimethylsilane (7.8 mL, 55 mmol) in THF (50 mL) at -78 °C. After stirring at this temperature for 30 min, freshly distilled (Z)-3-TMS hexenal (3.6 g, 36.7 mmol, Z:E \approx 85:15) was added dropwise and stirring continued for 30 min at -78°C before the cooling bath was removed and the mixture stirred at ambient temperature for 1 h. The solution was poured into aq. sat. NH₄Cl (100 mL), and the aqueous layer extracted with Et₂O (3 x 50mL), the combined organic layers dried (Na₂SO₄) and concentrated in *vacuo*. Flash chromatography of the residue (silica gel, hexanes/EtOAc, $98:2 \rightarrow 95:5$) gave product **12** (6.1 g, 84%). ¹H NMR (400 MHz, CDCl₃): $\delta = 0.17$ (s, 9H), 0.98 (t, J = 7.5, 3H), 1.8 (br s, 1H), 2.03-2.14 (m, 2H), 2.44-2.50 (m, 2H), 4.38 (t, J = 6.2, 1H), 5.38-5.47 (m, 1H), 5.57-5.66 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): $\delta = -0.2$, 14.2, 20.8, 35.5, 62.4, 89.5, 106.2, 122.7, 135.9; IR (film): $\tilde{\nu} = 3341$, 3013, 2962, 2176, 1456, 1407, 1334, 1305, 1249, 1125, 1041, 1002, 961, 886, 838, 759, 698; MS (EI): m/z (%) 196 (1), 181 (22), 167 (10), 151 (5), 127 (81), 122 (7), 99 (100), 91 (12), 83 (7), 75 (37), 55 (16), 41 (19), 29 (6); HRMS (EI): m/z: calcd for C₁₁H₂₀OSi [M⁺]: 196.12834, found: 196.12817. Characteristic signals of the *E*-isomer: ¹³C NMR (100 MHz, CDCl₃): $\delta = -0.3$, 13.7, 25.7, 40.9, 137.2.

(Z)-1-Oct-5-en-1-yn-3-ol (13). K_2CO_3 (5 g, 36 mmol) was added to solution of compound 12 (3.40 g, 17.3 mmol) in methanol (50 mL) and the suspension stirred for 30 min. The mixture was poured into aq. sat. NH₄Cl (100 mL), the aqueous layer extracted with Et₂O (3 x 50mL), and the combined organic phases dried (Na₂SO₄) and concentrated *in vacuo*. Flash chromatography of the residue (silica, pentane/Et₂O, 9:1 \rightarrow 4:1) gave product 13 as a colorless oil (2.10 g, 98%). ¹H NMR (400 MHz, CDCl₃): δ = 0.98 (t, *J* = 7.5, 3H), 1.78 (br s, 1H), 2.05-2.14 (m, 2H), 2.46 (d, *J* = 2.1, 1H) 2.48-2.52 (m, 2H), 4.40 (dt, *J* = 6.2, 2.1, 1H), 5.40-5.49 (m, 1H), 5.60-5.68 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ =14.2, 20.8, 35.4, 61.8, 72.9, 84.4, 122.3, 136.2; IR (film): \tilde{V} = 3325 (br), 3297, 3013, 2964, 2934, 2875, 1456, 1405, 1304, 1122, 1037, 969, 867, 795; MS (EI): *m/z* (%): 124 (0.2), 109 (12), 95 (23), 91 (26), 70 (38), 69 (35), 67 (35), 55 (62), 53 (15), 41 (100); Characteristic signals of the *E*-isomer: ¹H NMR (400 MHz, CDCl₃): δ = 1.00 (t, *J* = 7.3), 2.40-2.45 (m), 4.37 (dt, *J* = 6.0,

2.1).

(1E,5Z)-1-(TributyIstannyI)octa-1,5-dien-3-ol (14). Bu₃SnH (6.1 mL, 22.7 mmol) was added dropwise over 30 min via syringe pump to a stirred solution of alkyne 13 (1.89 g, 15.2 mmol) and (PPh₃)₂PdCl₂ (220 mg, 0.31 mmol, 2 mol%) in THF (50 mL) at 0 °C. The mixture was stirred at 0 °C for 30 min before the solvent was evaporated. Flash chromatography of the residue (silica, hexanes/EtOAc, 99:1 \rightarrow 98:2) gave product **14** as a colorless oil (3.72 g, 59 %). ¹H NMR (400 MHz, CDCl₃): δ = 0.89 (t, *J* = 7.3, 15H), 0.97 (t, *J* = 7.6, 3H), 1.25-1.36 (m, 6H), 1.45-1.55 (m, 6H), 1.56 (s, 1H), 2.01-2.11 (m, 2H), 2.28-2.34 (m, 2H), 4.07-4.16 (m, 1H), 5.31-5.40 (m, 1H), 5.51-5.61 (m, 1H), 6.03 (dd, *J* = 19.1, 5.1, 1H), 6.17 (dd, *J* = 19.1, 1.2, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 9.5, 13.7, 14.2, 20.7, 27.2, 29.1, 35.0, 74.7, 123.9, 127.8, 135.0, 150.1; IR (film): \tilde{V} = 3329, 2957, 2924, 2872, 2852, 1601, 1463, 1418, 1363, 1418, 1376, 1338, 1292, 1249, 1179, 1070, 1039, 988, 961, 872, 768, 688, 661; MS (EI): *m/z* (%) 359 (100), 303 (23), 251 (6), 233 (4), 177 (27), 137 (35), 119 (7), 95 (2), 67 (7), 55 (4), 41 (5); HRMS (EI): *m/z*: calcd for C₂₀H₄₀OSn [*M*⁺]: 439.20067, found: 439.19998.


(2Z,4E,8Z)-1-((tert-Butyldimethylsilyl)oxy)undeca-2,4,8-trien-6-yl acetate (16). CuTC (2.2 g, 11.7

OH

OTBS


mmol) was added to a stirred solution of stannane **14** (3.23 g, 7.78 mmol) and alkenyl iodide **15** (2.73 g, 9.16 mmol) in degassed *N*-methyl-2-pyrrolidone (20 mL) at 0 °C and the resulting mixture stirred at 0 °C for 1 h,

during which time the color of the originally tan suspension turned deep red and later back tan/grey. The mixture was diluted with *tert*-butyl methyl ether (20 mL). Celite^{*} (ca. 5 g) was added and the suspension stirred for 5 min, before it was filtered. The residue was carefully rinsed with *tert*-butyl methyl ether (ca. 100mL) and the combined filtrates were washed with water (100 mL) and aq. sat. NH₄Cl (50 mL) before they were dried (Na₂SO₄) and concentrated *in vacuo*. Flash chromatography of the residue (silica, hexanes/EtOAc, 98:2 \rightarrow 95:5) furnished the desired alcohol (\approx 2.5 g) which contained tin impurities. ¹H NMR (400 MHz, CDCl₃): δ = 0.08 (s, 6H), 0.90 (s, 9H), 0.97 (t, *J* = 7.5, 3H), 1.67 (d, *J* = 3.9, 1H), 2.02-2.11 (m, 2H), 2.26-2.39 (m, 2H), 4.16-4.25 (m, 1H), 4.36 (dd, *J* = 6.4, 1.6, 2H), 5.31-5.39 (m, 1H), 5.50-5.62 (m, 2H), 5.72 (dd, *J* = 15.2, 6.2, 1H), 5.96-6.03 (m, 1H), 6.49 (ddt, *J* = 15.2, 11.2, 1.2, 1.1]; ¹³C NMR (100 MHz, CDCl₃): δ = -5.1, 14.2, 18.3, 20.7, 25.9, 35.2, 59.7, 71.9, 123.5, 123.9, 125.3, 128.1, 131.3, 135.4, 136.7; IR (film): $\tilde{\nu}$ = 3329, 2957, 2924, 2872, 2852, 1601, 1463, 1418, 1376, 1338, 1292, 1249, 1179, 1070, 1039, 988, 961, 872, 768, 688, 661; MS (EI): *m/z* (%) 296 (1), 279 (1), 239 (5), 227 (100), 211 (21), 197 (3), 169 (12), 147 (12), 133 (8), 115 (13), 105 (17), 95 (75), 75 (65), 67 (32), 57 (5), 41 (29); HRMS (ESI): *m/z*: calcd for C₁₇H₃₂O₂SiNa [*M*+Na⁺]: 319.20638, found: 319.20664.



Ac₂O (1 mL, 10.6 mmol) was added dropwise to a stirred solution of this impure product (2.5 g), Et₃N (1.8 mL, 13 mmol) and DMAP (52 mg, 5 mol%) in CH₂Cl₂ (30 mL) at 0 °C. The mixture was stirred at 0 °C for 1 h, before the reaction was quenched with aq. sat. NaHCO₃ (50 mL). The aqueous layer

was extracted with *tert*-butyl methyl ether (3 x 50 mL), the combined extracts dried (Na₂SO₄) and concentrated *in vacuo*. Flash chromatography of the residue (silica, hexanes/EtOAc, 99:1 \rightarrow 98:2) gave product **16** (2.45 g, 93 % over two steps). ¹H NMR (400 MHz, CDCl₃): $\delta = 0.07$ (s, 6H), 0.90 (s, 9H), 0.56 (t, *J* = 7.5, 3H), 1.99-2.09 (m, 2H), 2.04 (s, 3H), 2.29-2.48 (m, 2H), 4.28-4.32 (m, 2H), 5.23-5.35 (m, 2H), 5.45-5.66 (m, 3H), 5.93-6.00 (m, 1H), 6.48 (ddt, *J* = 15.2, 11.2, 1.1, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = -5.1$, 14.1, 20.7, 21.2, 18.3, 25.9, 32.3, 59.7 73.9, 122.8, 127.4, 127.9, 132.1, 132.2, 134.8, 170.2; IR (film): $\tilde{V} = 3016$, 2957, 2930, 2857, 1739, 1370, 1231, 1079, 1018, 834, 774; MS (EI): *m/z* (%) 338 (0.2), 281 (1), 269 (3), 227 (4), 209 (4), 173 (1), 159 (4), 147 (26), 139 (2), 117 (100), 95 (14), 75 (31), 67 (9), 57 (2), 43 (13); HRMS (EI): *m/z*: calcd for C₁₉H₃₄O₃SiNa [*M+Na*⁺]: 361.21694, found: 361.21725.




(4E,7Z)-3-((Z)-3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)deca-4,7dienoic acid (17). A solution of acetate 16 (1.37 g, 4.05 mmol) in THF (4 mL)

was added dropwise to a solution of freshly prepared LDA (0.5 M in THF, 9.6

mL, 4.8 mmol) at –78 °C. After stirring for 5 min, a solution of TBSCI (1 м in THF/HMPA (3:2), 6 mL, 6 mmol) was introduced and the resulting mixture warmed to ambient temperature and stirred for 4 h. For work up, the mixture was poured into aq. sat. NH₄Cl (40 mL), the aqueous layer extracted with tert-butyl methyl ether (3 x 30 mL), and the combined extracts dried (Na₂SO₄) and concentrated in vacuo.

The crude silyl ester thus obtained was dissolved in MeOH (20 mL) and the solution cooled to 0 °C before K₂CO₃ (615 mg, 4.4 mmol) was added. The resulting suspension was stirred at 0 °C for 30 min before it was poured into aq. sat. NH₄Cl (50 mL + 50 mL water). The aqueous phase was extracted with tert-butyl methyl ether (3 x 50 mL), the combined organic layers were dried (Na₂SO₄) and concentrated in vacuo, and the residue purified by flash chromatography (silica, hexanes/EtOAc, 9:1 \rightarrow 8:2) to give acid **17** (1.27 g, 93 %). ¹H NMR (400 MHz, CDCl₃): δ = 0.06 (s, 6H), 0.90 (s, 9H), 0.95 (t, J = 7.5, 3H), 1.97-2.07 (m, 2H), 2.32-2.50 (m, 2H), 2.69-2.76 (m, 2H), 3.42-3.51 (m, 1H), 4.22-4.30 (m, 2H), 5.22-5.52 (m, 5H), 5.53-5.61(m, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = -5.2$, 14.2, 18.3, 20.4, 25.9, 30.1, 37.2, 40.1, 59.6, 126.3, 129.4, 130.6, 130.6, 130.9, 132.6, 177.6; IR (film): \tilde{v} = 3014, 2957, 2929, 2857, 1710, 1471, 1463, 1410, 1361, 1253, 1161, 1087, 1005, 965, 938, 834, 774, 716, 669; MS (EI): *m*/*z* (%) 305 (0.4), 281 (12), 263 (6), 237 (1), 206 (5), 161 (12), 147 (33), 137 (4), 105 (12), 91 (19), 75 (100), 69 (9), 55 (7), 41 (12); HRMS (EI): *m/z*: calcd for C₁₉H₃₄O₃SiNa [*M*+*Na*⁺]: 361.21694, found: 361.21731.

(4E,7Z)-tert-Butyl



3-((Z)-3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)deca-4,7-dienoate (18). 2,4,6-Trichlorobenzoyl chloride (1.2 mL, 7.6 mmol) was added to the solution of acid 17 (1.30 g, 3.83 mmol) and Et₃N (1.2 mL, 8.6 mmol) in toluene (40 mL). After stirring for 30 min, DMAP (500 mg, 4.1 mmol) and t-BuOH (3 mL) were introduced and stirring continued for 48 h. The mixture


was then poured into aq. sat. NaHCO₃ (50 mL) and the aqueous layer extracted with pentane (3 x 20 mL). The combined organic phases were dried (Na_2SO_4) and concentrated in vacuo, and the residue purified by flash chromatography (silica, hexane/tert-butyl methyl ether, $200:1 \rightarrow 100:1$) to furnish ester **18** (1.11 g, 73%). ¹H NMR (400 MHz, CDCl₃): δ = 0.06 (s, 6H), 0.89 (s, 9H), 0.95 (t, J = 7.6, 3H), 1.42 (s, 9H), 1.97-2.07 (m, 2H), 2.18-2.33 (m, 2H), 2.71-2.74 (m, 2H), 3.36-3.46 (m, 1H), 4.26 (dt, J = 6.0, 1.7, 2H), 5.21-5.47 (m, 5H), 5.50-5.57 (m, 1H); 13 C NMR (100 MHz, CDCl₃): δ = -5.1, -5.1, 14.2, 18.3, 26.0, 28.1, 30.1, 37.9, 41.7, 59.6, 80.3, 126.4, 128.8, 130.3, 131.1, 131.2, 132.5, 171.2; IR (film): \tilde{v} = 3010, 2959, 2930, 2857, 1731, 1472, 1462, 1391, 1367, 1253, 1148, 1087, 1006, 965, 835, 775, 717, 669; MS (EI): m/z (%) 337 (2), 321 (15), 305 (2), 281 (85), 263 (24), 237 (4), 206 (31), 189 (12), 171 (18), 161 (44), 147 (100), 119 (19), 105 (19), 91 (27), 75 (90), 57 (26), 41 (8). HRMS (EI): m/z: calcd for C₂₃H₄₂O₃SiNa [*M*+*Na*⁺]: 417.27954, found: 417.27964.

(4E,7Z)-tert-Butyl 3-((Z)-3-hydroxyprop-1-en-1-yl)deca-4,7-dienoate. TBAF (1 M in THF, 1.2 mL, 1.2

mmol) was added to a stirred solution of ester 18 (313 mg, 0.79 mmol) in THF (8 mL). After stirring for 1 h, all volatile materials were evaporated and $^{-OH}$ the residue purified by flash chromatography (silica, hexanes/EtOAc, 9:5 \rightarrow 4:1) to give the title compound as a colorless syrup (210 mg, 95 %). ¹H NMR


(400 MHz, CDCl₃): δ = 0.95 (t, J = 7.5, 3H), 1.42 (s, 9H), 1.97-2.07 (m, 2H), 2.23 (br s, 1H), 2.24 (dd, J = 15.5, 9.6, 1H), 2.39 (dd, J = 15.5, 5.2, 1H), 2.69-2.75 (m, 2H), 3.53-3.64 (m, 1H), 4.04 (dd, J = 12.5, 6.4, 1H), 4.31 (ddd, J = 12.5, 7.9, 1.2, 1H), 5.25-5.49 (m, 5H), 5.67-5.75 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 14.2, 20.4, 28.1, 30.1, 36.9, 41.2, 58.4, 80.9, 126.3, 128.9, 129.0, 131.2, 132.6, 134.0, 171.9; IR (film): \tilde{v} = 3431, 3009, 2966, 2934, 2875, 1727, 1456, 1429, 1392, 1367, 1298, 1254, 1146, 1019, 966, 843, 728 MS (EI): *m/z* (%) 263 (1), 224 (2), 206 (30), 191 (5), 177 (22), 161 (10), 147 (57), 117 (41), 95 (46), 91 (100), 79 (40), 67 (29), 57 (87), 41 (69), 29 (35); HRMS (ESI): *m/z*: calcd for C₁₇H₂₈O₃Na [*M*+*Na*⁺]: 303.19307, found: 303.19294.

(4E,7Z)-tert-Butyl 3-((Z)-3-bromoprop-1-en-1-yl)deca-4,7-dienoate (19). A solution of PPh₃ (297 mg,



1.1 mmol) in CH₂Cl₂ (1 mL) was added to the solution of (4*E*,7*Z*)-*tert*-butyl 3-((*Z*)-3-hydroxyprop-1-en-1-yl)deca-4,7-dienoate (210 mg, 0.75 mmol) and CBr₄ (373 mg, 1.1 mmol) in CH₂Cl₂ (5 mL) at 0 °C. The mixture was stirred at 0 °C for 20 min before the reaction was quenched with aq. sat. NH₄Cl (5 mL).


The organic phase was extracted with *tert*-butyl methyl ether (3 x 10 mL), the combined organic layers were dried (Na₂SO₄) and concentrated *in vacuo*, and the residue purified by flash chromatography (silica, hexane/*tert*-butyl methyl ether, 99:1) to give bomide **19** (237 mg, 92 %). ¹H NMR (400 MHz, CDCl₃): δ = 0.95 (t, *J* = 7.5, 3H), 1.42 (s, 9H), 1.95-2.07 (m, 2H), 2.22-2.40 (m, 2H), 2.73 (brt, *J* = 6.5, 2H), 3.50-3.61 (m, 1H), 3.94-4.00 (m, 1H), 4.05-4.12 (m, 1H), 5.25-5.55 (m, 5H), 5.69-5.78 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 14.2, 20.4, 27.1, 28.1, 30.2, 37.1, 41.2, 80.6, 125.7, 126.2, 129.6, 130.3, 132. 8, 135.9, 170.9; IR (film): \tilde{v} = 3009, 2967, 2933, 2874, 1727, 1455, 1392, 1367, 1252, 1204, 1155, 1136, 1070, 1037, 966, 921, 869, 845, 766; MS (EI): *m/z* (%) 286 (1), 271 (2), 227 (7), 207 (77), 189 (6), 161 (20), 147 (100), 133 (10), 119 (26), 105 (32), 95 (56), 79 (28), 67 (17), 57 (61), 41 (45); HRMS (ESI): *m/z*: calcd for C₁₇H₂₇O₂BrNa [*M*+*Na*⁺]: 365.10867, found: 365.10856.



3-((Z)-hex-1-en-4-yn-1-yl)deca-4,7-dienoate (20). A solution of 1-propynylmagnesium bromide (0.5 M in THF, 2.8 mL, 1.4 mmol) was added to solid Cul (26.6 mg, 0.14 mmol) at -15 °C and the resulting mixture
stirred at this temperature for 30 min before a solution of bromide 19 (234 mg, 0.68 mmol) in THF (2 mL) was introduced. After stirring for 3 h at -10

°C, the reaction was quenched with aq. sat. NH₄Cl (25 mL). The aqueous layer was extracted with *tert*-butyl methyl ether (3 x 25 mL), the combined organic phases were dried (Na₂SO₄) and concentrated *in vacuo*, and the residue purified by flash chromatography (silica, hexane/*tert*-butyl methyl ether, 98:2) to give product **20** (202 mg, 98 %), which must be stored in the freezer. ¹H NMR (400 MHz, CDCl₃): $\delta = 0.94$ (t, J = 7.5, 3H), 1.42 (s, 9H), 1.76 (t, J = 2.6, 2H), 1.96-2.06 (m, 2H), 2.15-2.35 (m, 2H), 2.71 (br t, J = 6.6, 2H), 2.89-2.95 (m, 2H), 3.40-3.50 (m, 2H), 5.22-5.50 (m, 6H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 3.5$, 14.2, 17.4, 20.4, 28.1, 30.2, 37.3, 41.6, 75.5, 77.2, 80.3, 125.6, 126.5, 128.8, 130.9, 132.0, 132.4, 171.2; IR (film): $\tilde{\nu} = 3010$, 2966, 2920, 1729, 1456, 1431, 1367, 1293, 1256, 1176, 1145, 1087, 1019, 966, 911, 845, 797, 705; MS (EI): *m/z* (%) 287 (1), 246 (4), 231 (4), 217 (11), 187 (29), 177 (32), 171 (19), 157 (42), 143 (41), 131 (99), 117 (49), 105 (48), 91 (56), 79 (33), 67 (17), 57 (100), 41 (65); HRMS (ESI): *m/z*: calcd for C₂₀H₃₀O₂Na [*M*+*Na*⁺]: 325.21380, found: 325.21369.

Undeca-1,9-diyn-1-yltrimethylsilane. Tf₂O was added dropwise to a solution of non-7-yn-1-ol (2.2 g,



15.7 mmol) and pyridine (1.35 mL, 16.7 mmol) in CH_2Cl_2 (60 ml) at -15 °C and the resulting mixture stirred at this temperature for 1h before it was diluted with hexane (60 mL) and filtered through Celite^{*}, which was carefully rinsed with hexane. The combined filtrates were concentrated *in vacuo* (keeping the bath temperature < 20°C) to give the crude triflate as a colorless syrup (4.07 g, 95 %), which was used in the next step without delay.

*n*BuLi (1.6 M in hexane, 12 mL, 19.2 mmol) was slowly added to a stirred solution of ethynyl-trimethylsilane (3.8 mL, 21 mmol) in THF (60 mL) at -78 °C and the resulting solution stirred at 0 °C for 30 min. The mixture was then cooled to -78 °C before a solution of the crude triflate (4.05 g, 14.9


mmol) in THF (15 mL) was introduced. The mixture was warmed to 0 °C, stirred for 1 h, the reaction quenched with aq. sat. NH₄Cl (50 mL) and the aqueous phase extracted with hexane (3 x 50 mL). The combined extracts were dried (Na₂SO₄) and concentrated *in vacuo*, and the residue purified by flash chromatography (silica, hexane/*tert*-butyl methyl ether, 200:1) to give the title compound as a colorless syrup (2.90 g, 84%). ¹H NMR (400 MHz, CDCl₃): δ = 0.14 (s, 9H), 1.34-1.42 (m, 4H), 1.43-1.52 (m, 4H), 1.77 (t, *J* = 2.6, 3H), 2.08-2.15 (m, 2H), 2.21 (t, *J* = 7.1, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 0.2, 3.4, 18.6, 19.8, 28.3 (2C), 28.5, 28.9, 75.4, 79.2, 84.3, 107.6; IR (film): \tilde{V} = 2935, 2859, 2174, 1248, 837, 758, 697 cm⁻¹; MS (EI): *m/z* (%) 220 (2), 205 (12), 192 (3), 177 (9), 163 (3), 145 (14), 131 (11), 117 (6), 109 (7), 97 (13), 83 (9), 73 (100), 67 (6), 59 (35), 53 (5), 43 (6); HRMS (EI): *m/z*: calcd for C₁₄H₂₄Si [*M*⁺]: 220.16473, found: 220.16494.

Undeca-1,9-diyne. K₂CO₃ (2.8 g, 20.3 mmol) was added to solution of undeca-1,9-diyn-1-

yltrimethylsilane (913 mg, 4.14 mmol) in methanol (50 mL) and the suspension stirred for 4 h before it was poured into aq. sat. NH₄Cl (100 mL). The aqueous layer was extracted with pentane (3 x 50 mL) and the combined extracts dried (Na₂SO₄) and concentrated *in vacuo* to give the title compound as a colorless oil which was pure enough for further use (601 mg, 98%). ¹H NMR (400 MHz, CDCl₃): δ = 1.35-1.44

(m, 4H), 1.45-1.57 (m, 4H), 1.77 (t, J = 2.6, 3H), 1.93 (t, J = 2.6, 1H), 2.09-2.15 (m, 2H), 2.18 (dt, J = 7.0, 2.6, 2H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 3.4$, 18.3, 18.7, 28.3, 28.3, 28.4, 28.9, 68.1, 75.4, 79.2, 84.6; IR (film): $\tilde{V} = 3298$, 2934, 2859, 1459, 1434 cm⁻¹; MS (EI): m/z (%) 147 (1), 133 (6), 119 (22), 105 (92), 91 (100), 79 (67), 67 (57), 53 (49), 41 (58), 27 (31); HRMS (EI): m/z: calcd for C₁₁H₁₆ [M^+]: 148.12520, found: 148.12517.


Methyl dodeca-2,10-diynoate. nBuLi (1.6 M in hexane, 4 mL, 6.4 mmol) was slowly added to a stirred



solution of undeca-1,9-diyne (917 mg, 6.2 mmol) in THF (20 mL) at -78 °C and the resulting mixture stirred at this temperature for 30 min before methyl chloroformate (500 μ L, 6.4 mmol) was introduced. The resulting mixture was stirred at -78 °C for 3h before the reaction was quenched with aq. sat. NH₄Cl (50 mL). The aqueous phase was extracted with *tert*-butyl methyl ether (3 x 30 mL), the combined extracts were dried (Na₂SO₄) and concentrated *in vacuo*,

and the residue was purified by flash chromatography (silica, hexane/*tert*-butyl methyl ether, 99:1 \rightarrow 95:5) to afford the title compound as a colorless syrup (1.06 g, 83%). ¹H NMR (400 MHz, CDCl₃): δ = 1.36-1.43 (m, 4H), 1.44-1.52 (m, 2H), 1.54-1.63 (m, 2H), 1.77 (t, *J* = 2.5, 3H), 2.08-2.15 (m, 2H), 2.33 (t, *J* = 7.1, 2H), 3.75 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 3.4, 18.6, 18.6, 27.4, 28.2, 28.3, 28.8, 52.5, 72.9, 75.5, 79.1, 89.8, 154.2; IR (film): $\tilde{\nu}$ = 2936, 2859, 2234, 1712, 1434, 1248, 1075, 751; MS (EI): *m/z* (%) 205 (4), 191 (14), 175 (11), 163 (31), 147 (33), 131 (37), 124 (21), 119 (50), 111 (13), 105 (100), 98 (11), 91 (82), 79 (64), 67 (64), 59 (27), 53 (62), 41 (61), 27 (29); HRMS (ESI+): *m/z*: calcd for C₁₃H₁₈O₂Na [*M*⁺ + Na]: 229.11990, found: 229.12012.

tert-Butyl-3-oxo-2-((5Z,8E,11Z)-tetradeca-5,8,11-trien-2-yn-7-yl)tetradeca-4,12-diynoate (21). A




solution of ester **20** (260 mg, 0.86 mmol) in THF (0.5 mL) was slowly added to a stirred solution of freshly prepared LDA (0.5 M in THF, 1.67 mL, 0.84 mmol) at -78 °C. The mixture was stirred at this temperature for 25 min before a solution of methyl dodeca-2,10-diynoate (225 mg, 1.10 mmol) in THF (0.5 mL) was introduced. Stirring was continued at -78 °C for 3 h

and for 1 h at 0 °C. The reaction was quenched with aq. sat. NH₄Cl (5 mL), the aqueous layer

extracted with *tert*-butyl methyl ether (3 x 10 mL), the combined organic phases were dried (Na_2SO_4) and concentrated in vacuo, and the residue was purified by flash chromatography (silica, hexane/tert-butyl methyl ether, 100:1) to give product 21 (304 mg, 76 %). This product can be stored at -20°C for short periods of time. It exists as a mixture of (at least) three species (keto- and enol forms) in a ratio of \approx 3:3:4 (NMR). ¹H NMR (400 MHz, CDCl₃): δ = 0.93 (t, J = 7.5, 0.3 x 3H), 0.93 (t, J = 7.5, 0.3 x 3H), 0.94 (t, J = 7.5, 0.4x3H), 1.35-1.54 (m, 6H), 1.41 (s, 0.3 x 3H), 1.42 (s, 0.3 x 3H), 1.48 (s, 0.4 x 3H), 1.54-1.66 (m, 2H), 1.95-2.07 (m, 2H), 2.08-2.15 (m, 2H), 2.37 (dt, J = 7.0, 1.5, 1H), 2.44 (t, J = 7.1, 1H), 2.61-2.76 (m, 2H), 2.84-3.04 (m, 2H), 3.40 (dd, 9.6, 5.7, 0.6H), 3.75-3.88 (m, 0.6H), 3.28-3.35 (m, 0.4H), 5.18-5.61 (m, 5.6H), 5.69-5.77 (m, 0.4H), 12.51 (s, 0.3H); ¹³C NMR (100 MHz, CDCl₃, resolved signals of the *ketone/enol* mixture): δ = 3.4, 3.4, 3.5, 14.2, 14.2, 17.5, 17.6, 18.6, 18.7, 19.0, 19.5, 20.4, 27.5, 27.8, 27.9, 28.0, 28.2, 28.3, 28.3, 28.4, 28.6, 28.8, 28.9, 30.1, 30.1, 30.2, 40.1, 40.1, 40.3, 66.5, 66.8, 75.2, 75.3, 75.4, 75.5, 75.5, 75.5, 77.1, 79.0, 79.1, 80.1, 80.3, 82.0, 82.3, 96.6, 96.6, 100.0, 111.2, 125.1, 126.1, 126.2, 126.7, 127.1, 127.2, 128.1, 128.3, 129.0, 129.2, 130.7, 130.9, 131.6, 131.9, 132.2, 132.6, 132.6, 152.5, 166.2, 166.3, 172.1, 181.3, 181.4; IR (film): $\widetilde{\nu}$ = 3008, 2934, 2859, 2212, 1733, 1676, 1631, 1587, 1456, 1392, 1368, 1250, 1148, 1098, 1035, 966, 910, 846, 732, 679; HRMS (EI): *m/z*: calcd for C₃₂H₄₄O₃Na [*M*+*Na*⁺]: 499.31827, found: 499.31808.


6-(Non-7-yn-1-yl)-2-oxo-3-((5Z,8E,11Z)-tetradeca-5,8,11-trien-2-yn-7-yl)-2H-pyran-4-yl acetate (23).



A solution of XPhosAuNTf₂ (**22**) (0.7 mg, 5 mol%) and compound **21** (6.5 mg, 13.6 μ mol) in MeNO₂/HOAc (350 μ L, 4:1) was stirred for 14 h at ambient temperature. For work up, the solvents were distilled off under vacuum while cooling the mixture to 0 °C. The residue was dissolved in CH₂Cl₂ (1 mL), and Et₃N (30 μ L) and Ac₂O

(15 µL) were added at 0 °C. After stirring for 30 min at 0 °C, the reaction was quenched with aq. sat. NaHCO₃ (3 mL), the aqueous layer extracted with *tert*-butyl methyl ether (3 x 5 mL), the combined organic phases were dried (Na₂SO₄) and concentrated *in vacuo*, and the residue quickly passed through a short pad of silica, eluting with a gradient of hexane/*tert*-butyl methyl ether (99:1 \rightarrow 95:5) to give product **23** as a colorless syrup (4.6 mg, 73 %). This product can be stored at -20°C only for short periods of time. ¹H NMR (400 MHz, CDCl₃): δ = 0.94 (t, *J* = 7.5, 3H), 1.29-1.51 (m, 6H), 1.59-1.68 (m, 2H), 1.76 (t, *J* = 2.6, 3H) 1.77 (t, *J* = 2.5, 3H), 1.97-2.06 (m, 2H), 2.08-2.15 (m, 2H), 2.29 (s, 3H), 2.44 (brt, *J* = 7.7, 2H), 2.73 (br t, *J* = 6.5, 2H), 2.83-3.00 (m, 2H), 4.44-4.51 (m, 2H), 5.25-5.34 (m, 1H), 5.36-5.63 (m, 3H), 5.59-5.67 (m, 1H), 5.73-5.81 (m, 1H), 5.89 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 3.4, 3.5, 14.2, 17.4, 18.6, 20.5, 21.0, 26.6, 28.1, 28.5, 28.8, 30.1, 33.5, 36.8, 75.6, 75.6, 76.9, 79.1, 101.6, 116.5, 126.3, 126.5, 128.9, 129.4, 129.6, 132.6, 158.1, 163.7, 163.7, 167.1; IR (film): $\tilde{\nu}$ = 3011, 2932, 2858, 1778, 1718, 1649, 1583, 1432, 1368, 1180, 1012, 1009, 972, 910, 876, 801, 728; MS (EI): *m/z* (%): 462 (19), 420 (63), 391 (16), 377 (27), 367 (48), 351 (70), 341 (32), 325 (100), 311 (9), 297 (11), 270 (13), 227 (16), 201 (20), 173 (35), 159 (66), 131 (26), 145 (20), 117 (28), 109 (33), 91 (49), 69 (53), 55 (56), 43 (84). HRMS (ESI): *m/z*: calcd for C₃₀H₃₈O₄Na [*M+Na*⁺]: 485.26623, found: 485.26654.


(Z)-2-((1E,4Z)-Hepta-1,4-dien-1-yl)-16-oxo-15-oxabicyclo[12.2.2]octadeca-1(17),3,14(18)-trien-6-



yn-17-yl acetate (25). Dried MS 5Å powder (100 mg) was added to a solution of compound **23** (7.8 mg, 17 μ mol) in toluene (17 mL) and the resulting suspension stirred for 30 min before a solution of complex **24** (10 mM in toluene, 85 μ L, 0.85 μ mol, 5 mol%) was introduced. After stirring for 30 min at ambient temperature, the mixture was filtered through a pad of Celite[®], which was thoroughly rinsed with *tert*-butyl methyl ether. The combined filtrates were concentrated *in vacuo* and the residue purified by flash chromatography (silica, hexane/*tert*-butyl methyl ether,

98:2 → 95:5) to give cycloalkyne **25** (6.1 mg, 88 %, ca. 1:1 mixture of atropisomers). ¹H NMR (500 MHz, CDCl₃): δ = 0.94 (t, *J* = 7.5, ½·3H), 0.94 (t, *J* = 7.5, ½·3H), 1.06-1.38 (m, 5H), 143-1.55 (m, 1H), 1.66-1.87 (m, 2H), 1.97-2.05 (m, 2H), 2.05-2.18 (m, 2H), 2.20-2.27 (m, ½H), 2.26 (s, ½·3H), 2.28-2.36 (m, ½H), 2.36 (s, ½·3H), 2.61-2.76 (m, 4H), 2.85-2.93 (m, ½H), 3.06-3.15 (m, ½H), 4.26 (brt, *J* = 7.0, ½H), 4.60-4.65 (m, ½H), 5.24-5.32 (m, 1H), 5.37-3.49 (m, 2½H), 5.51-5.54 (m, 1H), 5.78 (brdd, *J* = 10.3, 7.2, ½H), 5.83 (ddt, *J* = 15.4, 7.6, 1.6, ½H), 5.91 (brdd, *J* = 10.3, 6.3, ½H), 6.02 (s, ½H), 6.03 (s, ½H); ¹³C NMR (125 MHz, CDCl₃): δ = 14.2, 14.2, 17.8, 18.2, 18.6, 18.7, 20.4, 20.5, 20.9, 21.3, 24.8, 25.0, 27.7, 27.9, 28.3, 28.7, 28.9, 29.0, 30.1, 30.1, 34.6, 35.1, 35.8, 36.3, 76.9, 77.3, 79.1, 79.6, 101.9, 103.3, 117.6, 118.0, 125.5, 126.1, 126.3, 126.4, 129.2, 129.2, 129.4, 130.3, 131.7, 131.7, 132.6, 132.6, 156.3, 158.8, 162.5, 163.3, 163.7, 164.7, 166.7, 167.0; IR (film): $\tilde{\nu}$ = 3011, 2929, 2857, 1779, 1711, 1647, 1582, 1460, 1432, 1368, 1331, 1257, 1176, 1111, 1070, 1037, 1010, 968, 896, 872, 788, 727; MS (ESI): *m/z* (%) 341.2 (M+Na), 839.4 (2M+Na); HRMS (EI): *m/z*: calcd for C₂₆H₃₂O₄Na [*M+Na*⁺]: 431.21928, found: 431.21960.

Neurymenolide A Acetate (2). H₂ was bubbled through a mixture containing cycloalkyne 25 (5.5 mg,



13.5 µmol), Lindlar catalyst (5.5 mg), quinoline (20 µL) in EtOAc/1-hexene (2 mL, 1:1) for 10 min. The suspension was then stirred under H₂ (1 atm) for 1 h before it was filtered through a pad of Celite[®], which was thoroughly rinsed with *tert*-butyl methyl ether. The combined filtrates were concentrated *in vacuo* and the residue purified by flash chromatography (silica, hexane/*tert*-butyl methyl ether, 98:2 \rightarrow 95:5) to provide neurymenolide A acetate (**2**) (4.7 mg, 84 %) as a \approx 2:3 mixture of atropisomers. ¹H

NMR (500 MHz, CDCl₃): δ =0.94 (t, J = 7.5, 2/5x3H), 0.95 (t, J = 7.5, 3/5x3H), 1.02-1.41 (m, 6H), 1.54-1.71 (m, 1H), 1.71-1.98 (3H), 2.02 (qi, J = 7.4, 2H), 2.20-2.25 (m, 2/5H), 2.22 (s, 3/5x3H), 2.25-36 (m, 3/5H), 2.34 (s, 2/5x3H), 2.37-4.48 (m, 1H), 2.63-2.75 (m, 1H), 2.71-2.77 (m, 2H), 2.77-2.88 (m, 1H), 4.12-4.18 (m, 2/5H), 4.48-4.53 (m, 3/5H), 5.19-5.61 (m, 7+1/5H), 5.64-5.70 (m, 2/5H), 5.76-5.82 (m, 2/5H), 5.98 (3/5H), 6.01 (2/5H); ¹³C NMR (125 MHz, CDCl₃): δ = 14.2, 14.3, 20.4, 20.5, 20.9, 21.2, 24.2, 25.5, 25.8, 26.2, 26.4, 26.9, 26.9, 27.1, 27.1, 27.2, 27.4, 27.6, 30.1 (x2), 33.7, 33.8, 37.1, 37.5, 102.5, 103.7, 116.9, 117.3, 126.3, 126.3, 127.2, 127.5, 129.2, 129.3, 129.4, 129.4, 129.8, 129.8, 129.8, 130.0, 130.1, 130.2, 132.6, 157.2, 158.5, 162.1, 163.7, 164.2, 164.9, 166.7, 167.1; IR (film): $\tilde{\nu}$ = 3009, 2927, 2854, 1778, 1714, 1647, 1580, 1461, 1435, 1367, 1274, 1178, 1111, 1043, 1011, 967, 871, 788, 726, 698; MS (EI): m/z (%) 410 (69), 368 (100), 351 (11), 339 (24), 325 (14), 313 (10), 299 (96), 273 (33), 257 (11), 243 (7), 229 (7), 215 (8), 199 (13), 187 (10), 175 (13), 159 (15), 145 (15), 133 (16), 117 (22), 105 (23), 91 (42), 79 (33), 69 (48), 55 (42), 43 (71); HRMS (EI): m/z: calcd for C₂₆H₃₄O₄Na [*M*+*Na*⁺]: 433.23493, found: 433.23534.





Figure S2. Preparative HPLC (Shimadzu LC-8A/10A, YMC (150 mm, \emptyset 20 mm) ODS-A 5 μ m, MeCN/H₂O (9:1), 15 mL/min) allowed the two atropisomers of **2** to be separated; however, they equilibrate quickly in solution as evident from the HPLC traced recorded 6 min, 1 h, and 16 h after collection of the pure atropisomer.

Synthetic sample		Literature Data				
		r isomer	Minor i			
δ	δ	$\Delta \delta$	δ	$\Delta \delta$		
14.2			14.2	0		
14.3	14.2	0.1				
20.4	20.5	-0.1				
20.5			20.5	0		
20.9			20.9	0		
21.2	21.2	0				
24.2			25.5	-1.3		
25.5	25.5	0				
25.8			25.8	0		
26.2	26.2	0				
26.4	26.4	0				
26.9	26.9	0				
26.9			26.9	0		
27.1			27.1	0		
27.1	27.1	0				
27.2	27.2	0				
27.4			27.4	0		
27.6			27.6	0		
30.1			30.0	0.1		
30.1	30.0	0.1				
33.7	33.7	0				
33.8			33.8	0		
37.1	37.1	0				
37.5			37.5	0		
102.5			102.5	0		
103.7	103.7	0				
116.9			116.9	0		
117.3	117.3	0				
126.3	126.3	0				
126.3			126.3	0		
127.2	127.2	0				
127.5			127.5	0		
129.2	129.3	-0.1				
129.3			129.4	-0.1		
129.4			129.4	0		
129.4	129.4	0				
129.8			129.7	0.1		
129.8			129.8	0		
129.8	129.8	0				
130.0	130.0	0				
130.1			130.1	0		
130.2	130.2	0				
132.6	132.5	0.1				
132.6			132.6	0		
157.2			157.2	0		
158.5	158.5	0				
162.1			162.1	0		
163.7	163.7	0				
164.2	164.2	0				
164.9			165.0	-0.1		
166.7	166.6	0.1				
167.1			167.1	0		

Table S1. Comparison of the ¹³C NMR data (CDCl₃) of synthetic neurymenolide A acetate (**2**) with the reported data of the authentic sample.⁴

Neurymenolide A (1). K₂CO₃ (0.5 mg, 3.6 µmol) was added to solution of 2 (0.9 mg, 4.1 mmol) in



methanol (0.5 mL) at 0 °C and the suspension stirred at this temperature for 30 min. The mixture was poured into aq. sat. NH_4Cl (5 mL), the aqueous layer quickly extracted with *tert*-butyl methyl ether (3 x 5 mL), and the combined organic phases were dried (Na_2SO_4) and concentrated *in vacuo* to give crude neurymenolide A (**1**) which was pure enough to ensure identity with the natural product.⁴ Attempts to remove traces of impurities from the crude material lead to decomposition. ¹H NMR (500 MHz, CDCl₃): δ

= 0.95 (t, *J* = 7.5, 3H), 1.02-1.42 (m, 6H), 1.50-1.70 (m, 1H), 1.75-2.04 (m, 3H), 1.92-2.08 (m, 2H), 2.22-2.35 (m, 1H), 2.50-2.59 (m, 1H), 2.59-2.67 (m, 1H), 2.71-2.81 (m, 2H), 2.81-2.91 (m, 1H), 4.55-4.59 (m, 1H), 5.17-5-5.48 (m, 4H), 5.57-5.74 (m, 4H), 5.82 (s, 1H), 6.39 (s, 1H); ¹³C NMR (125 MHz, CDCl₃): δ = 14.2, 20.5, 25.6, 26.6, 26.9, 27.0, 27.1, 27.7, 30.0, 33.5, 36.5, 101.3, 103.8, 125.9, 126.6, 126.9, 129.4, 129.9, 131.0, 133.0, 135.5, 164.6, 165.1, 165.1; MS (EI): *m/z* (%) 368 (80), 353 (5), 339 (16), 325 (8), 313 (8), 299 (100), 273 (19), 257 (8), 243 (6), 229 (6), 215 (8), 201 (9), 187 (10), 175 (14), 159 (16), 145 (19), 133 (24), 117 (25), 105 (34), 91 (61), 79 (54), 69 (71), 55 (73), 41 (89); MS (ESI): 391.2 (100%, M+Na), 759.5 (37%, 2M+Na); HRMS (ESI): *m/z*: calcd for C₂₄H₃₂O₃Na [*M+Na*⁺]: 391.22436, found: 391.22408.


	$\Delta \delta$	
Synthetic sample (125 MHz)	Authentic sample (150 MHz)	
14.2	14.2	0
20.5	20.5	0
25.6	25.6	0
26.6	26.6	0
26.9	26.9	0
27.0	27	0
27.1	27.1	0
27.7	27.7	0
30.0	30	0
33.5	33.5	0
36.5	36.5	0
101.3	101.4	-0.1
103.8	103.9	-0.1
125.9	125.9	0
126.6	126.6	0
126.9	127	-0.1
129.4	129.4	0
129.9	129.9	0
131.0	131	0
133.0	132.9	0.1
135.5	135.2	0.3
164.7	164.7	0
165.1	165.1	0
165.1	165.1	0


Table S2. Comparison of the ¹³C NMR data (CDCl₃) of synthetic neurymenolide A with the published data.⁴


⁴ E. P. Stout, A. P. Hasemeyer, A. L. Lane, T. M. Daenport, S. Engel, M. E. Hay, C. R. Fairchild, J. Prudhomme, K. L. Roch, W. Aalbersberg, J. Kubanek, *Org. Lett.* **2009**, *11*, 225-228.


NMR SPECTRA


Pseudopyronine
















S20





S22

100


150


50

0 [ppm]


N -

200







trace impurities derive from the E-isomer contained in the commercial sample of (Z)-3-hexenal





trace impurities derive from the E-isomer contained in the commercial sample of (Z)-3-hexenal





trace impurities derive from the E-isomer contained in the commercial sample of (Z)-3-hexenal





















trace impurities derive from the E-isomer contained in the commercial sample of (Z)-3-hexenal







trace impurities derive from the E-isomer contained in the commercial sample of (Z)-3-hexenal













trace impurities derive from the E-isomer contained in the commercial sample of (Z)-3-hexenal







trace impurities derive from the E-isomer contained in the commercial sample of (Z)-3-hexenal










mixture of keto/enol tautomers









mixture of atropisomers






Neurymenolide A Acetate

mixture of atropisomers





Neurymenolide A

mixture of atropisomers

